<?xml version="1.0" encoding="UTF-8"?>
<ref id="B32-pharmaceutics-12-00688">
 <label>32.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Takahashi</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Hattori</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Yagi</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Murai</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Takai</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Ogawa</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Tanemura</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Fuji</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Kawashima</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Yamamoto</surname>
    <given-names>H.</given-names>
   </name>
  </person-group>
  <article-title>Optimization of ionic liquid-incorporated PLGA nanoparticles for treatment of biofilm infections</article-title>
  <source>Mater. Sci. Eng. C Mater. Biol. Appl.</source>
  <year>2019</year>
  <volume>97</volume>
  <fpage>78</fpage>
  <lpage>83</lpage>
  <pub-id pub-id-type="doi">10.1016/j.msec.2018.11.079</pub-id>
  <pub-id pub-id-type="pmid">30678968</pub-id>
 </element-citation>
</ref>
